Clinical trials: Headache Disorders
Migraine
Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines
The primary purpose of this study is to determine whether AMG 333 is safe and well tolerated in healthy subjects and subjects with migraines.
- Trial name
- NCT01953341
- Testing
- AMG 333
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Amgen
Migraine
A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
The purpose of this study is to characterize the pharmacokinetics of MK-1602 in the treatment of acute migraine, including the influence of demographic and other variables on MK-1602 pharmacokinetics, and to evaluate the…
- Trial name
- NCT01657370
- Testing
- MK-1602, Rescue medication
- Volunteers
- 195 people
- Sponsor
- Allergan
Migraine, Headache
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
The purpose of this study is to determine whether a fixed-dose combination of naratriptan + naproxen is effective compared each monotherapy for the acute treatment of migraine.
- Trial name
- Atenéia (NCT01390324)
- Testing
- Fixed-dose combination of naratriptan+naproxen, Naratriptan, Naproxen
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Migraine
Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study
Preventive pharmacologic therapies for migraine aim to reduce attack frequency and duration and improve quality of life; however, their use, overall benefit and adherence are often limited.
- Trial name
- NCT07487701
- Testing
- Nerivio REN device
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Theranica
Migraine Disorders
BOTOX® Prophylaxis in Patients With Chronic Migraine
This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic…
- Trial name
- NCT01432379
- Testing
- botulinum toxin Type A
- Where
- 4 sites in Germany, Spain and 2 more
- Volunteers
- 1,168 people
- Sponsor
- Allergan
Migraine
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine
This is a prospective, randomized, vehicle-controlled, double-blind, multi-center study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic…
- Trial name
- NCT03488563
- Testing
- B244, Vehicle
- Where
- 22 sites in United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- AOBiome LLC
Migraine
A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
This study will provide additional efficacy data for rizatriptan when used for an acute migraine attack in patients already taking topiramate for migraine prophylaxis.
- Trial name
- NCT00812006
- Testing
- rizatriptan benzoate
- Volunteers
- 108 people
- Sponsor
- Organon and Co
Cluster Headache
Pathway CH S&E Registry
Monitor the safety and performance of the Pulsante Microstimulator System.
- Trial name
- SER (NCT02440776)
- Where
- 9 sites in Denmark, Germany and 3 more
- Volunteers
- 30 people
- Sponsor
- Autonomic Technologies, Inc.
Chronic Migraine
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound.
- Trial name
- ATO-BOTOX (NCT05216263)
- Testing
- Atogepant
- Where
- 29 sites in United States
- Volunteers
- 75 people
- Sponsor
- AbbVie
Migraine
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD1910, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
- Trial name
- NCT04197349
- Testing
- ALD1910, Sumatriptan
- Where
- Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Migraine Disorders
Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks
Canvert-M (manufactured by Alasht Pharmed Co. Iran) is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc.
- Trial name
- NCT07093138
- Testing
- Canvert-M (Produced by Alasht Pharmed co. Iran)
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Alasht Pharmed
Migraine in Children
A Survey Study to Assess the Accessibility of the Nerivio Device At School
This is a retrospective survey-study to assess the accessibility, preference, and frequency of adolescents using Nerivio by itself, in combination with pharmacological medications, or not at all, in the school setting.
- Trial name
- NCT06180577
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Theranica
Migraine
Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine
To evaluate the effects of a single sc administration of TEZAMPANEL at one of three different dosage levels compared to placebo, employing traditional measures of efficacy and safety in the treatment of a single episode of acute…
- Trial name
- NCT00567086
- Testing
- TEZAMPANEL
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- TorreyPines Therapeutics
Episodic Migraine
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03939312
- Testing
- Atogepant
- Where
- 113 sites in United States
- Volunteers
- 685 people
- Sponsor
- Allergan
Migraine
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
To evaluate the effect of erenumab compared to placebo on disability in employed subjects with episodic migraine (EM) who have previously failed 1 or more migraine preventive treatments.
- Trial name
- NCT03912337
- Testing
- Erenumab
- Where
- 28 sites in United States
- Volunteers
- 29 people
- Sponsor
- Amgen
Migraine
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101.
- Trial name
- NCT06728553
- Testing
- MTX101
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Manistee Therapeutics
Migraine
Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients
The primary purpose of this study is to determine whether erenumab is safe and well tolerated in healthy adults and migraine patients.
- Trial name
- NCT01688739
- Testing
- Erenumab
- Where
- Belgium
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Amgen
Migraine
Probiotics for the Prophylaxis of Migraine
This study aims to understand the efficacy of two probiotic interventions as prophylaxes of migraine symptoms in individuals diagnosed with episodic migraine.
- Trial name
- MIGR_PRO2 (NCT04305522)
- Testing
- Probiotic 1, Probiotic 2
- Where
- 2 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Biopolis S.L.
Migraine Disorders
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.
- Trial name
- NCT00963937
- Testing
- Sumatriptan 25 mg, Sumatriptan 50 mg
- Where
- 16 sites in Japan
- Volunteers
- 178 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- PROMISE 2 (NCT02974153)
- Testing
- ALD403 (Eptinezumab)
- Where
- 144 sites in United States, Belgium and 11 more
- Volunteers
- 1,121 people
- Sponsor
- Alder Biopharmaceuticals, Inc.